HomeCompareMKGAF vs DIVO

MKGAF vs DIVO: Dividend Comparison 2026

MKGAF yields 2.04% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKGAF wins by $107.4K in total portfolio value· pulled ahead in Year 5
10 years
MKGAF
MKGAF
● Live price
2.04%
Share price
$122.45
Annual div
$2.50
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.2K
Annual income
$57,634.11
Full MKGAF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — MKGAF vs DIVO

📍 MKGAF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKGAFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKGAF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKGAF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKGAF
Annual income on $10K today (after 15% tax)
$173.61/yr
After 10yr DRIP, annual income (after tax)
$48,988.99/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, MKGAF beats the other by $48,154.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKGAF + DIVO for your $10,000?

MKGAF: 50%DIVO: 50%
100% DIVO50/50100% MKGAF
Portfolio after 10yr
$84.4K
Annual income
$29,307.90/yr
Blended yield
34.71%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKGAF buys
0
DIVO buys
0
No recent congressional trades found for MKGAF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKGAFDIVO
Forward yield2.04%6.49%
Annual dividend / share$2.50$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%0%
Portfolio after 10y$138.2K$30.7K
Annual income after 10y$57,634.11$981.68
Total dividends collected$109.9K$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MKGAF vs DIVO ($10,000, DRIP)

YearMKGAF PortfolioMKGAF Income/yrDIVO PortfolioDIVO Income/yrGap
1$11,012$311.88$11,349$649.42$337.00DIVO
2$12,273$490.13$12,833$688.83$560.00DIVO
3$13,912$779.56$14,459$727.90$547.00DIVO
4$16,146$1,261.05$16,238$766.49$92.00DIVO
5← crossover$19,365$2,088.77$18,179$804.47+$1.2KMKGAF
6$24,296$3,575.17$20,293$841.71+$4.0KMKGAF
7$32,398$6,401.21$22,591$878.14+$9.8KMKGAF
8$46,847$12,181.47$25,087$913.65+$21.8KMKGAF
9$75,264$25,137.47$27,791$948.18+$47.5KMKGAF
10$138,167$57,634.11$30,718$981.68+$107.4KMKGAF

MKGAF vs DIVO: Complete Analysis 2026

MKGAFStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKGAF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this MKGAF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKGAF vs SCHDMKGAF vs JEPIMKGAF vs OMKGAF vs KOMKGAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.